3.86

0.52% -0.02

After Hours: 3.92 0.06 +1.55%

Aardvark Therapeutics Inc (AARD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Aardvark Therapeutics Inc stock is traded at $3.86, with a volume of 68,796. It is down -0.52% in the last 24 hours and down -23.11% over the past month. Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Previous Close:

$3.88

Open:

$3.86

24h Volume:

68,796

Relative Volume:

0.42

Market Cap:

$84.48M

Revenue:

Net Income/Loss:

$-69.87M

P/E Ratio:

-1.2029

EPS:

-3.2089

Net Cash Flow:

$-61.75M

1W Performance:

-18.05%

1M Performance:

-23.11%

6M Performance:

-24.02%

1Y Performance:

-72.29%

1-Day Range:

$3.77

$3.977

1-Week Range:

$3.77

$4.8771

52-Week Range:

$3.35

$16.60

Aardvark Therapeutics Inc Stock (AARD) Company Profile

Name

Aardvark Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(858) 225-7696

Address

4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

AARD's Discussions on Twitter

Compare AARD vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AARD Aardvark Therapeutics Inc	3.86	84.48M	0	-69.87M	-61.75M	-3.2089
VRTX Vertex Pharmaceuticals Inc	508.75	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.34	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.27	53.22B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.08	42.32B	5.76B	514.49M	1.10B	4.4813

Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-26	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Mar-02-26	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-02-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-02-26	Downgrade	Stifel	Buy → Hold
Jan-28-26	Initiated	B. Riley Securities	Buy
Dec-23-25	Initiated	Oppenheimer	Outperform
Dec-12-25	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Raymond James	Strong Buy
Nov-07-25	Initiated	BTIG Research	Buy
Sep-29-25	Initiated	Stifel	Buy
Jun-30-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Initiated	BofA Securities	Buy
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight
Mar-10-25	Initiated	Morgan Stanley	Overweight
Mar-10-25	Initiated	RBC Capital Mkts	Outperform

View All

Aardvark Therapeutics Inc Stock (AARD) Latest News

Oct 11, 2026

AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD - GlobeNewswire Inc.

Oct 11, 2026

AARD 截止日期通知：知名律師事務所 ROSEN 提醒 Aardvark Therapeutics, Inc. 投資人，應於證券集體訴訟重要期限 10 月 13 日之前委任法律律師 – AARD - GlobeNewswire Inc.

Oct 11, 2026

Oct 10, 2026

URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th - GlobeNewswire Inc.

Oct 10, 2026

Oct 09, 2026

AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff DeadlineHBSS - GlobeNewswire Inc.

Oct 09, 2026

Oct 08, 2026

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD - GlobeNewswire Inc.

Oct 08, 2026

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.

Oct 08, 2026

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors - GlobeNewswire Inc.

Oct 08, 2026

Oct 06, 2026

Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

Oct 06, 2026

AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS - GlobeNewswire

Oct 06, 2026

Oct 05, 2026

AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Investors to Secure Counsel Before Important October 13 Deadline - GlobeNewswire Inc.

Oct 05, 2026

Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th - The Daily Tribune News

Oct 05, 2026

Oct 03, 2026

Did You Lose Money on Aardvark Therapeutics, Inc. (AARD)? Levi & Korsinsky Urges Investors to Act Before October 13, 2026 - ACCESS Newswire

Oct 03, 2026

Oct 02, 2026

AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - the-dispatch.com

Oct 02, 2026